865,349 Shares in Teladoc Health, Inc. $TDOC Acquired by Freestone Grove Partners LP

Freestone Grove Partners LP acquired a new stake in shares of Teladoc Health, Inc. (NYSE:TDOC) in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 865,349 shares of the health services provider’s stock, valued at approximately $7,338,000.

Several other large investors have also recently bought and sold shares of the company. Man Group plc acquired a new stake in Teladoc Health in the second quarter worth $6,881,000. Jupiter Topco LLC acquired a new position in shares of Teladoc Health in the 2nd quarter valued at $607,000. ABS Investment Management LLC acquired a new position in shares of Teladoc Health in the 2nd quarter valued at $1,513,154. EFG International AG bought a new stake in shares of Teladoc Health in the 2nd quarter valued at $35,000. Finally, Canada Pension Plan Investment Board bought a new stake in shares of Teladoc Health in the 2nd quarter valued at $296,000. Institutional investors own 76.82% of the company’s stock.

Teladoc Health Trading Up 2.4%

Shares of NYSE TDOC opened at $6.51 on Friday. The company has a fifty day moving average price of $7.94 and a 200 day moving average price of $6.64. The firm has a market cap of $1.18 billion, a PE ratio of -6.58 and a beta of 2.12. Teladoc Health, Inc. has a 1-year low of $4.40 and a 1-year high of $9.89.

Teladoc Health (NYSE:TDOC) last posted its quarterly earnings data on Wednesday, July 29th. The health services provider reported ($0.21) earnings per share for the quarter, topping the consensus estimate of ($0.25) by $0.04. The company had revenue of $606.93 million during the quarter, compared to analysts’ expectations of $615.44 million. Teladoc Health had a negative return on equity of 12.15% and a negative net margin of 7.13%.Teladoc Health’s revenue for the quarter was down 4.0% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.19) earnings per share. Teladoc Health has set its Q3 2026 guidance at -0.300–0.200 EPS and its FY 2026 guidance at -1.000–0.750 EPS. Equities research analysts forecast that Teladoc Health, Inc. will post -0.89 EPS for the current year.

Insider Buying and Selling at Teladoc Health

In related news, insider Carlos Nueno sold 6,196 shares of Teladoc Health stock in a transaction dated Tuesday, June 2nd. The stock was sold at an average price of $7.63, for a total value of $47,275.48. Following the sale, the insider owned 57,671 shares of the company’s stock, valued at approximately $440,029.73. The trade was a 9.70% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Adam C. Vandervoort sold 7,906 shares of the business’s stock in a transaction that occurred on Tuesday, June 2nd. The stock was sold at an average price of $7.63, for a total value of $60,322.78. Following the transaction, the insider directly owned 110,261 shares in the company, valued at $841,291.43. This trade represents a 6.69% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last three months, insiders sold 39,195 shares of company stock worth $299,058. Company insiders own 0.70% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts recently commented on the company. Canaccord Genuity Group dropped their price objective on Teladoc Health from $11.00 to $10.00 and set a “buy” rating on the stock in a research note on Thursday, July 30th. Weiss Ratings restated a “sell (d-)” rating on shares of Teladoc Health in a report on Wednesday, August 19th. Citigroup dropped their price target on Teladoc Health from $11.00 to $7.50 and set a “neutral” rating on the stock in a research report on Monday, August 3rd. Finally, Bank of America lifted their price objective on Teladoc Health from $9.00 to $10.50 and gave the company a “buy” rating in a report on Tuesday, July 7th. Five analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $7.54.

Teladoc Health Company Profile

Teladoc Health, Inc is a leading global provider of virtual healthcare services, offering on-demand medical consultations via phone, video, and mobile app platforms. The company connects patients with licensed physicians and specialists for non-emergency medical issues, mental health support, dermatology, and chronic condition management. By leveraging digital technologies and data analytics, Teladoc aims to enhance accessibility, reduce healthcare costs, and improve patient outcomes through personalized care plans and remote monitoring.

Teladoc’s service portfolio includes general medical visits, behavioral health sessions, expert medical services for complex cases, and wellness programs designed to support chronic disease management such as diabetes, hypertension, and heart disease.